This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. This protein undergoes autocatalytic cleavage to release the pro-peptide and mature chain. The pro-peptide and mature chain are associated through non‑covalent interactions and with a calculated MW of 13.8 kDa and 59.9 kDa respectively. The protein migrates as 17 kDa and 63-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>92% as determined by reduced SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human PCSK9, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 92%.
Immobilized Biotinylated Human PCSK9, Avitag,His Tag (Cat. No. PC9-H82E7) can bind PCSK9 Mab, Human IgG with a linear range of 0.05-1.5 ng/mL. The biotinylated PCSK9 is coated at 1 μg/mL (100 μL/well) on a streptavidin coated plates (Routinely tested).
FACS analysis shows that Biotinylated Human PCSK9, Avitag,His Tag (Cat. No. PC9-H82E7) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 1.502-2.378 μg/mL.
Authors: Wang CK, Amiss AS, Weidmann J
Journal: J Biol Chem 2020
Authors: J Carter, et al
Journal: US20190177730A1 2019
Authors: Wang CK, et al.
Journal: ACS Chem Biol 2018
Authors: Chen Z, et al.
Journal: Nat Chem 2018
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.